AIP
APGE

Arrowpoint Investment Partners’s Apogee Therapeutics APGE Stock Holding History

Arrowpoint Investment Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,007
Closed -$337K – 132
2026
Q1 		$337K Sell
4,007
-2,317
-37% -$168K 0.3% 53
2025
Q4 		$477K Buy
+6,324
New +$398K 0.07% 75

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Arrowpoint Investment Partners's APGE Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 4,007 shares — an estimated $337K sold.

Arrowpoint Investment Partners first reported a position in APGE in Q4 2025 and held it in 2 quarters. The position peaked at $477K in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 4,007 Apogee Therapeutics shares in Q2 2026, an estimated $337K.
  • Arrowpoint Investment Partners first reported a position in Apogee Therapeutics in Q4 2025 and held it in 2 quarters.
  • Arrowpoint Investment Partners's Apogee Therapeutics position peaked at $477K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.